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Influenza, an infectious respiratory disease, is one of the main 
causes of excess winter deaths (EWDs) in Europe. Annual flu epi-
demics are associated with high morbidity and mortality rates, 
especially among the elderly, those with underlying health condi-
tions and pregnant women.
Health Care Workers (HCWs) are also considered at high risk of 
both contracting influenza and spreading the virus to vulnerable 
patients.
During the 2014/2015 season, the excess winter mortality rates 
observed in countries of the northern hemisphere (EuroMOMO 
network) and in Italy (+13%) were strongly related to the inten-
sity of influenza circulation. 
Influenza vaccination is the most important public health inter-
vention to prevent seasonal influenza transmission and infection. 
However, to date, influenza vaccination coverage reported in 
Europe (including high-risk groups) is still largely unsatisfactory.
This study analyzes some international and European guidelines 
on influenza vaccination and the rationale that underlies evi-
dence-based public health intervention for the prevention of influ-
enza among the principal high-risk groups: a) the elderly (sub-
jects aged 65 years or older); b) subjects with underlying health 
conditions; c) pregnant women; d) healthcare workers. 
Only by achievement recommended influenza vaccination cover-
age among high-risk groups in all European countries can we 
reduce the burden of disease. 
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Summary
Introduction
Influenza, an infectious respiratory disease caused by 
influenza viruses, is one of the main causes of excess 
winter deaths (EWDs) in Europe [1-3]. Annual flu epi-
demics are associated with high morbidity and mortality 
rates, especially among the elderly and those with un-
derlying health conditions; these groups are particularly 
at risk of developing influenza complications, such as 
bacterial pneumonia [3, 4].
During the last winter season (2014/2015), the excess of 
deaths due to all causes observed in fourteen European 
countries among people ≥ 65 years old coincided with an 
increase in the detection of influenza A(H3N2) viruses 
by the European influenza surveillance system  [5]. In 
particular, in England and Wales the highest number of 
EWDs since 1999/2000 was recorded, while in Italy a 
13% rate of EWDs was reported [6, 7].
Influenza vaccination is the most important public 
health intervention to prevent seasonal influenza trans-
mission and infection [3, 4]. In Europe, guidelines and 
preventive policies for influenza vaccination are primar-
ily focused on protecting individuals at higher risk, both 
directly by vaccinating these subjects and indirectly by 
vaccinating those who could infect them [3].
This review aims to analyze international and European 
guidelines on influenza vaccination and the rationale 
that underlies evidence-based public health intervention 
for the prevention of influenza. In particular, we will 
discuss the evidence regarding influenza vaccination 
among the four principal groups at risk, which constitute 
key target for preventive strategies: the elderly (subjects 
aged 65 years or older), subjects with underlying health 
conditions, pregnant women and healthcare workers.
Influenza vaccination among the elderly
In the temperate zones, an increase in expected mortality 
levels is frequently observed among the elderly during 
the winter season; this increase, however, largely de-
pends on the season or country [5, 8, 9].
Excess mortality may be related to two main factors: 
a) seasonal influenza, especially during seasons with a 
prevalent circulation of influenza A(H3N2), and other 
respiratory tract infections; b) environmental conditions 
(e.g. cold spells) [6, 9].
In recent years, several studies have shown the world-
wide impact of influenza infection on excess winter 
mortality rates in the elderly (Tab. I) [5-11].
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In Europe, a network named EuroMOMO (European 
monitoring of excess mortality for public health action 
network) monitors weekly and “real-time” all-cause 
age-specific excess mortality in European countries 
through a standardized approach that allows pooling of 
results [12].
In February and March 2012, an increased number of 
excess deaths among the elderly was observed in Euro-
pean member countries of the EuroMOMO  [12]. This 
reported excess mortality coincided with late increased 
influenza activity and was related to a prevalent detection 
of influenza A(H3N2) by both sentinel and non-sentinel 
sources (approximately 95%) [11]. This profile of isola-
tion was very different from previous influenza seasons, 
when influenza A(H1N1) was predominantly isolated; in 
these seasons, only a minor impact on mortality among 
the elderly was observed in countries  of the northern 
hemisphere [6, 11]. More recently, a greater number of 
excess deaths among the elderly was observed during 
the last winter season (2014/15) and was strongly related 
to the intensity of influenza circulation, showing a cor-
relation between weeks with excess mortality and me-
dium or high influenza activity (80%) [5-7]. Moreover, 
the last influenza season in the northern hemisphere 
was similar to the 2011/2012 season, in that A(H3N2) 
virus was predominant (56% of detections across the 
European Community)  [13]. It is expected that a win-
ter season in which influenza A(H3N2) is predominant 
will have a higher impact on mortality among the elderly 
than a season with predominant influenza A(H1N1) or 
a season with low influenza A transmission  [5, 9]. In-
fluenza A(H3N2) virus has been recognized as having 
a noticeably greater effect on the elderly than influenza 
virus A(H1N1), which is particularly virulent in younger 
people [6]. In addition, in the 2014/15 influenza season, 
most influenza  A(H3N2) viruses characterized in Eu-
rope exhibited antigenic differences in comparison with 
those included in the vaccine formulation; higher mor-
bidity and mortality rates were observed in vaccinated 
populations  [14, 15]. Finally, during the last influenza 
season in Europe, a lineage B mismatch of the influenza 
vaccine was frequently observed, which contributed to 
reducing vaccine efficacy  [16, 17]. These data provide 
strong support for the inclusion of both influenza B lin-
eages in seasonal influenza vaccines [17].
Trends in influenza circulation are strongly correlated 
with excess winter mortality among the elderly in the 
northern hemisphere and Europe, highlighting the heavy 
burden of disease  [5]. In this context, influenza vac-
cination guidelines issued by the principal public 
health authorities recommend 75% coverage of sea-
sonal influenza vaccination for individuals aged 
≥  65  years  [18-20]. However, in the 2011/2012 and 
2012/2013 seasons, vaccination coverage in the el-
derly reached this threshold only in two European 
countries (the United Kingdom and the Netherlands). 
All other EU member states reported lower vaccination 
coverage, varying from 60% (Italy and Spain) to 5-10% 
(Estonia and Latvia) [21, 22]. In Italy during the last in-
fluenza season, influenza vaccination coverage was es-
timated to have decreased by 25-30% from the overall 
2014 level [7, 22]. These data suggested that only high 
vaccination coverage rates can reduce influenza circula-
tion, the impact of infection and possible variations in 
vaccine effectiveness among the elderly [18, 19].
Influenza vaccination among subjects 
with chronic diseases
Individuals with underlying health conditions are the 
core target of influenza vaccination. Every disease exac-
erbates the risk of influenza infection and, in particular, 
of influenza complications or death  [19]. The associa-
tion of several chronic diseases could constitute a seri-
ous risk factor for unvaccinated subjects during the in-
fluenza season [22].
According to public health guidelines, all individuals 
aged > 6 months with at least one chronic illness that 
constitutes a risk factor for influenza or its complica-
tions should be vaccinated [20, 21]. The comorbidities 
in which influenza vaccination is recommended are re-
ported in Table II.
Despite the strong recommendation to vaccinate sub-
jects with comorbidities, the observed coverage rate 
remains low. Indeed, there is great debate inside the sci-
entific community, especially among general practitio-
ners and medical specialists, regarding the efficacy and 
safety of influenza vaccines in chronically ill subjects. 
One concern regards vaccine efficacy (VE), as such co-
morbidities are claimed to determine a lower immuno-
logical response. However, research has demonstrated a 
good efficacy profile of influenza vaccines among these 
population groups [22-25].
An extensive review and meta-analysis published 
in 2012 assessed influenza vaccination among immuno-
Tab. I. Influenza-attributable excess winter mortality (EWDs) in the elderly.
Authors Country Age-class Years
Prevalence of EWDs 
attributable 
to influenza 
Influenza virus 
type
Matias et al. [10]
USA ≥ 75 years 1997-2009 71% A(H3N2)
USA ≥ 75 years 1997-2009 50-95% (during all seasons) B
Nielsen et al. [9] Denmark ≥ 65 years 1994-2010 82% A(H3N2)
Thiberville et al. [8] France ≥ 65 years 1999-2010 6.27 to 13.23 (per 100,000 inhab) A(H3N2)
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compromised patients [26]. The study demonstrated that 
transplant recipients and patients with human immuno-
deficiency virus (HIV) infection or cancer had signifi-
cantly lower odds of contracting influenza-like illness 
after vaccination. Moreover, compared with patients 
receiving placebo or no vaccination, vaccinated HIV-
positive patients had lower odds of laboratory-confirmed 
influenza. Influenza vaccination was generally well tol-
erated [26].
Another prospective, non-interventional cohort study 
was conducted during the 2010/2011 influenza season 
among more than 800 adult cancer patients in Israel [27]. 
A lower mortality rate was observed among vaccinated 
cancer patients than unvaccinated ones, even though a 
statistical association with complications due to influen-
za infection was not demonstrated [27]. Furthermore, a 
large (7,772 subjects with COPD aged ≥ 55 years) cohort 
study conducted from 1996 to 2008 in Taiwan by Sung 
et al. found a reduction in hospitalizations for acute 
coronary syndrome among vaccinated people [28]. The 
protective effects were observed in both sexes and all 
age-groups examined (55-64, 65-74, ≥ 75), regardless of 
influenza seasonality. When the patients were stratified 
according to the total number of vaccinations, the adjust-
ed Hazard Ratios (HRs) for acute coronary syndrome 
hospitalization were 0.48  for patients who received 
2-3 vaccinations and 0.20 for patients who received ≥ 4 
vaccinations [28].
Influenza vaccination was also associated with a 24% re-
duction in stroke risk in a case-control study conducted 
in the UK from 2001 to 2009 [29]. Specifically, stroke 
risk was significantly lower following early (September 
to mid-November), but not later, influenza vaccination 
(mid-November onwards) [29].
Influenza vaccination among pregnant 
women
Influenza may be a frequent infection during pregnan-
cy  [30,  31]. In particular, pregnant women appear to 
have an increased risk of severe disease, especially dur-
ing annual epidemics and pandemics [32, 33]. As report-
ed by Louie et al., the pandemic influenza A(H1N1) in 
2009 caused severe illness and death especially among 
pregnant and postpartum women  [34]. Conducted in 
California, their study analyzed all women hospital-
ized during the first wave of pandemic influenza (from 
April to August 2009), 42.6% (N = 102/239) of whom 
were pregnant or in postpartum. Overall, 18  pregnant 
and 4 postpartum women (22%) required intensive care, 
while 8% died  [34]. The severity of influenza among 
pregnant women observed in California is consistent 
with an increased risk of severe disease and the dispro-
portionate number of influenza-associated deaths that 
has been documented for seasonal influenza and pre-
vious pandemics  [35-37] The main difference was the 
rapid clinical deterioration observed in some patients 
in comparison with the typical course of seasonal influ-
enza [34].
Moreover, in the Hungarian case-control surveillance 
of congenital abnormalities conducted from 1980 to 
1996, Nandor et al. found a higher prevalence of mater-
nal influenza during the second and/or third month of 
pregnancy in newborns with cleft lip-palate, neural-tube 
defects and cardiovascular malformations. The authors 
supposed that the teratogenic effect due to influenza vi-
ruses was probably associated with fever, as this risk was 
reduced by the use of antifever drugs [38].
On the other hand, several studies have demonstrated 
the efficacy and safety of influenza vaccination dur-
ing the second and third trimesters of pregnancy. 
With regard to efficacy, Thompson et al. conducted a 
population-based case-control study during two con-
secutive influenza seasons (2010-2011 and 2011-2012) 
and showed a lower risk of Acute Respiratory Illness 
(ARI) associated with laboratory-confirmed influenza 
in vaccinated pregnant women  [35]. The reported VE 
was similar to that observed among all adults during 
these seasons (VE against influenza A and B: 44%; 
95% confidence interval 5-67%) [35, 36]. Moreover, a 
double-blind, randomized, placebo-controlled trial of 
influenza vaccine conducted in South Africa in 2011 
demonstrated that influenza vaccine was immunogen-
ic in both HIV-uninfected and HIV-infected pregnant 
women and provided partial protection for infants who 
were not exposed to HIV  [37]. With regard to safety, 
Ludvigsson et al. found no excess mortality in the off-
spring of women who had been vaccinated against in-
fluenza A(H1N1)pdm09 during pregnancy. Moreover, 
Tab. II. Chronic diseases that increase the risk of contracting influenza, for which influenza vaccination is strongly recommended (mod. from 
Ministero della Salute, 2016 [21]).
Chronic diseases
Respiratory and pulmonary diseases (COPD, asthma, cystic fibrosis etc.)
Heart diseases (all congenital or acquired heart conditions)
Diabetes mellitus or any other metabolic diseases (including individuals with BMI > 30)
Chronic renal or adrenal gland failure
Any type of cancer (also during radio- and chemotherapy)
Hematological diseases or hemoglobinopathies
Congenital or acquired immunodeficiency (pharmacological, AIDS etc.)
Chronic inflammatory bowel disease and inadequate intestinal absorption syndrome 
Chronic hepatic diseases
Neuromuscular diseases or any disease at risk for aspiration of respiratory secretions 
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the authors noted that maternal A(H1N1) vaccination 
during any trimester of pregnancy had no adverse ef-
fects on children in either the early neonatal period or 
early childhood  [39]. In 2015, McMillan et al. pub-
lished a review on safety outcomes of influenza vacci-
nation during pregnancy. In their quantitative analysis, 
maternal influenza vaccination was not associated with 
an increased risk of fetal death, spontaneous abortion 
or congenital malformations [40].
For all these reasons, international and national guide-
lines now strongly recommend influenza vaccination for 
all pregnant women in the second and third trimesters, 
in order to protect them and their children during late 
pregnancy and to protect their infants during the first six 
months after birth through the induction of immunity 
that would otherwise not be achievable [19-21]. 
Influenza vaccination among health-care 
workers
Influenza vaccination among health-care workers (HC-
Ws) is considered to be the most important strategy for 
preventing the transmission of influenza viruses to vul-
nerable patients and minimizing absenteeism among 
HCWs during annual epidemics  [19,  41,  42]. Indeed, 
hospitalized patients may acquire influenza not only 
from other patients or visitors but also from hospital em-
ployees. Elder et al. estimated a 20% influenza infec-
tion rate among HCWs each season [43]. Many HCWs 
continue working while infected, thereby spreading the 
virus  [43]. Therefore, vaccinating medical personnel 
against influenza is the most effective strategy for pre-
venting nosocomial influenza transmission and reducing 
influenza-like illness (ILI) mortality among elderly and 
high-risk patients [42, 44]. Although this is recognized 
and emphasized by all public health agencies world-
wide, influenza vaccination coverage among HCWs re-
main lower than 75% [19-21].
Adherence to influenza vaccination does not seem to de-
pend on physicians’ age or specialty  [45-48]. In some 
non-European countries, mandatory vaccination plays a 
decisive role in the vaccination of HCWs, and the im-
munization rates observed in such countries are very far 
from those observed in Europe [49, 50]. However, it is 
difficult to apply mandatory vaccination in the European 
context, for such reasons as staff morale, civil liberty 
and professional autonomy  [51]. Indeed, some studies 
have reported that HCWs prefer other strategies for pro-
moting influenza vaccination; specifically, it has been 
demonstrated that appropriate training through multi-
disciplinary courses, adequate university education and 
proactive attitudes on the part of coworkers can improve 
influenza vaccination coverage [51, 52].
One of the main goals of public health authorities should 
be to promote proper attitudes towards and knowledge 
of influenza vaccination among HCWs, since this is 
the best means of protecting both them and their pa-
tients. Moreover, HCWs should have appropriate skills 
in counseling patients with regard to the importance of 
influenza vaccination, especially among the high-risk 
classes of individuals analyzed in this review [52].
Conclusions
On the basis of the winter mortality rates observed in re-
cent years both in countries of the northern hemisphere 
and in Italy, influenza is one of the leading causes of 
death. In particular, the elderly, subjects with comorbidi-
ties, pregnant women and HCWs are at higher risk of 
contracting influenza and its complications. Worldwide, 
vaccination is the only recognized strategy for prevent-
ing influenza circulation, transmission and infection, 
and all principal sanitary authorities recommend vacci-
nation for these high-risk groups.
In the future, the most important target for preventive 
medicine will to achieve the recommended influenza 
vaccination coverage in all European countries, in order 
to reduce the burden of disease and minimize mortal-
ity [5-7, 53].
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